Harvard and the Canadian firm Atlas ink, establish a research program
Harvard University is at the forefront of medical research on cannabis and has chosen Atlas Biotechnologies as the founding partner of this initiative. Atlas will be exclusively the sole supplier of cannabis flower and its derivatives for research.
Atlas has committed 3 millions of Canadian dollars to the research program on the occasion of the opening of the new Institute of Phytomedicine and Medical Cannabis to be based at Harvard Medical School in Boston, unveiled last Sunday at Global Health Catalyst.
The Institute of Phytomedicine's (IPI) mission is to leverage the best scientific, technological and educational knowledge provided by Harvard and partner institutions to convert high-impact potential medicinal plants into evidence-based pharmaceutical quality products. for global health and economic development.
The academic partnership with the private sector could validate some treatments by proving the effectiveness of formulations, making these treatments more marketable.
Other industry partners with sponsored research commitments include: Flavocure Biotech Inc. Atlas Biotechnology Cannabis Science Inc.
As part of this collaboration, Atlas will provide cannabis products to Harvard Medical for testing purposes from its growers subsidiary, Canada Atlas Growers, and possibly to other US post-secondary institutions for the purpose of research and development.
The Canadian company's research with Harvard will focus on neurological disorders and pain.
"We, nor the director of Harvard Global Health Catalyst, have come across a group that involves a similar caliber of institutions and industries that are all working together to achieve the same goal," said Jeffrey Gossain, Director General Atlas. "By bringing all these groups together into one institute, we have created the best way to achieve unprecedented health and wealth through medicinal plants.
"As we move forward, more research on cannabis will make it easier for physicians to prescribe cannabis products for all these different symptoms," Gossain said.
"And that's a bit of the vision we have. Create the most reliable cannabis products in the world. And trust will be based on research and development that we do throughout the industry. "
Harvard's partnership with Atlas provides funding over the next three years based on targeted research goals. The first Atlas delivery is scheduled for July.
This new partnership comes into play just after the announcement, earlier this monththat one of the first investors in the Canadian cannabis market had donated 9 million dollars to share between Harvard Medical School and the Massachusetts Institute of Technology (MIT).